Tenax Therapeutics, Inc.(TENX): For the most recent quarter end, Tenax Therapeutics, Inc. reported Annual Earnings of $-0.15. For the most recent quarter end, TENX reported a surprise Earnings per Share of 11.76% . The consensus estimate for current quarter is $-0.14 and for the current fiscal year, the estimate is $-0.64. For the Next fiscal year, the estimate is $-0.38 based on the consensus.
According to the corporate earnings calendar, Tenax Therapeutics, Inc. will release next earnings on with an estimated EPS consensus of $-0.14. Based on the consensus of stock financial advisors the stock has a price target of $7.25. Current year estimate on EPS consensus is $-0.64.
For Dividend Investing Stock Market Traders Tenax Therapeutics, Inc. has a Dividend Yield of 0% with an Annual Dividend of $0.
Company has reported several Insider transactions to the SEC, on Nov 29, 2016, Gerald T Proehl (director) purchased 29,882 shares at 1.67 per share price.On Nov 19, 2015, Ronald R Blanck (director) purchased 1,900 shares at 3.20 per share price.
Tenax Therapeutics, Inc. (NASDAQ:TENX) witnessed a decline in the market cap on Wednesday as its shares dropped 1.65% or 0.013 points. After the session commenced at $0.8155, the stock reached the higher end at $0.8241 while it hit a low of $0.76. With the volume soaring to 1,089,855 shares, the last trade was called at $0.7736. The company has a 52-week high of $2.94. The company has a market cap of $22 million and there are 28,119,934 shares in outstanding. The 52-week low of the share price is $0.415.
Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market. The Company specializes in creating pharmaceuticals and medical devices in the fields of oxygen therapeutics, blood substitutes, and liquid ventilation and implanted glucose sensing. Tenax Therapeutics Inc., formerly known as Oxygen Biotherapeutics, Inc., is based in United States.